Article | Open | Published:

Japanese GWAS identifies variants for bust-size, dysmenorrhea, and menstrual fever that are eQTLs for relevant protein-coding or long non-coding RNAs

Scientific Reportsvolume 8, Article number: 8502 (2018) | Download Citation


Traits related to primary and secondary sexual characteristics greatly impact females during puberty and day-to-day adult life. Therefore, we performed a GWAS analysis of 11,348 Japanese female volunteers and 22 gynecology-related phenotypic variables, and identified significant associations for bust-size, menstrual pain (dysmenorrhea) severity, and menstrual fever. Bust-size analysis identified significant association signals in CCDC170-ESR1 (rs6557160; P = 1.7 × 10−16) and KCNU1-ZNF703 (rs146992477; P = 6.2 × 10−9) and found that one-third of known European-ancestry associations were also present in Japanese. eQTL data points to CCDC170 and ZNF703 as those signals’ functional targets. For menstrual fever, we identified a novel association in OPRM1 (rs17181171; P = 2.0 × 10−8), for which top variants were eQTLs in multiple tissues. A known dysmenorrhea signal near NGF replicated in our data (rs12030576; P = 1.1 × 10−19) and was associated with RP4-663N10.1 expression, a putative lncRNA enhancer of NGF, while a novel dysmenorrhea signal in the IL1 locus (rs80111889; P = 1.9 × 10−16) contained SNPs previously associated with endometriosis, and GWAS SNPs were most significantly associated with IL1A expression. By combining regional imputation with colocalization analysis of GWAS/eQTL signals along with integrated annotation with epigenomic data, this study further refines the sets of candidate causal variants and target genes for these known and novel gynecology-related trait loci.


Traits related to primary and secondary sexual characteristics exhibit variation in the human population. Such traits in females, which can be broadly grouped as female or gynecology-related phenotypes, have a great impact during puberty as well as subsequent day-to-day adult life and may be influenced during development both by environmental and genetic factors. Among these traits, the menstrual cycle and breast development play vital roles in the reproductive process in the human female, with the menstrual cycle being required for the preparation of the uterus for pregnancy and breast development required for nursing offspring. Menarche and breast development are landmarks of female puberty, and the development of mammary glands and menstrual cycle is controlled by female sex steroid hormones, estrogen and progesterone.

Gynecology-related phenotypes also relate to reproductive health, sexual attractiveness and gynecologic disorders. For example, epidemiological studies reported that early menarche is associated with endometrial cancer, breast cancer and type II diabetes, and other studies reported that breast size is associated with breast cancer risk1 and type II diabetes2. In addition, dysmenorrhea (menstrual pain) was associated with subsequent endometriosis3 and deep infiltrating endometriosis4, which is a severe type of endometriosis. Furthermore, age-at-menarche and dysmenorrhea is associated with familial history5,6.

Recently, several genome-wide association studies (GWAS) have analyzed a number of gynecology-related phenotypes and successfully identified genomic loci associated with age at menarche7,8, age at menopause, dysmenorrhea9,10, endometriosis11,12,13,14, and breast size15. Furthermore, these genetic variants are reported to be shared by other traits and diseases16.

In this study, we performed a GWAS analysis of gynecology-related phenotypes and identified associations for menstruation associated phenotypes and breast size in the Japanese population.


For this study, 11379 female participants in two study stages (LL01 = 5751, LL02 = 5628) were solicited to answer questions about gynecology-related phenotypes and provide DNA for Genome-wide association study (GWAS) analysis of those traits. From a custom Affymetrix Axiom genotyping array, we extracted 536506 variants and after applying genotype and sample quality control procedures, we used 11348 LL01 + LL02 samples that clustered with 1000 Genomes Project East Asian samples17 based on Principal Component Analysis (PCA) (Supplementary Fig. S1).

We examined twenty-two phenotypic variables related to pre-menstrual and menstrual symptoms/issues, vaginal discharge, and bust-size. Sample counts and demographics (Age and BMI) for the gynecology-related phenotypes are shown in Supplementary Table S1; note that bust-size analyses only had phenotype data from the LL02 stage. Based on a previous analysis of effective SNP counts (ME) for a similarly-sized platform and the JPT population18, we set a single GWAS P-value cut-off of 1.21 × 10−7 (0.05/411,521) for calling nominal associations and called strongly associated signals those that achieved a multiple-testing adjusted P-value cut-off of P < 5.5 × 10−9 (P < 1.21 × 10−7/22 female-related phenotypes). Association signals were found for three primary phenotypes: bust-size, dysmenorrhea pain severity, and menstrual fever impact on daily life (Quality-of-life: QOL impact) (Supplementary Fig. S2; Supplementary Worksheet S1). In addition, two secondary phenotypes related to dysmenorrhea possessed significant loci that overlapped those identified for dysmenorrhea pain severity: 1) if dysmenorrhea had an impact on daily life (QOL impact), and 2) pain medicine use during menstruation. Manhattan plots were produced using summary statistics based imputation to impart a more comprehensive view of association peaks, but identification of association signals was based solely on the genotyped data. We observed negligible inflation of genome-wide test statistics by QQ-plot and λGC, which ranged from 0.9926 to 1.0288 (Supplementary Fig. S3).

Neighboring associated SNPs were grouped into clusters, and genotype-based imputation was run using 1000 Genomes Project Phase 3 reference haplotypes, followed by conditional regression analysis on the top SNP in each region to identify signal boundaries (Table 1; Supplementary Worksheet S1). To rank and order variants in a signal, we measured linkage disequilibrium (LD) between top SNPs and associated variants using the standard r2 and D’ values as well as a measure that we abbreviate as r2 equiv , which reflects the relative signal strength (RSS) of a particular variant with respect to a top variant (see Methods). To identify candidate causal variants within linked variants, we annotated SNPs for overlap with gene models, protein-coding variants, epigenetic/regulatory function, eQTLs, and previous publication resources (Supplementary Worksheets S2S6).

Table 1 Summary of significant loci for gynecology-related phenotypes.

Bust-size association signals

Bust-size was analyzed using a linear regression analysis of bra-sizes coded as integer values (see Methods) with PC1 and PC2 from PCA and body-mass index (BMI) included as covariates. We identified two significant loci for bust-size, with a strongly associated locus at chr6:151.92-151.99 Mb having a top SNP (rs6557160) that achieved P = 1.72 × 10−16 (Fig. 1a), and another nominally associated locus at chr8:36.76–36.91 Mb with a top variant (rs146992477) with P = 6.25 × 10–9 (Fig. 2a). Since GWAS of mostly European (EUR) ancestry samples had previously analyzed bust-size and the related phenotype of mammographic-density, we examined associated SNPs from the NHGRI/EBI GWAS Catalog (downloaded 8/31/2017; reported P < 5 × 10−8)19,20 for three earlier studies15,16,21 for significant association with bust-size in our Japanese (JPT) ancestry population samples. From genome-wide summary statistics imputed using DISTMIX22, we replicated/validated six of eighteen previous association signals (SNPs with FDR < 0.1 in our data: Table 2; all previous SNPs: Supplementary Table S2). Those six signals overlapped the genes AREG-BTC (two independent signals), CCDC170-ESR1, KCNU1-ZNF703, NTN4-USP44, and MKL1-SGSM3-TNRC6B.

Figure 1
Figure 1

Bust-size chr6:151.92–151.99 Mb (CCDC170) locus. (a) Plot of −log10(P-values) around association signal. Upper sub-panel displays points sized by LD r2 to the top SNP. Lower panel shows -log10(P-values) with (red circles) and without (black circles) conditioning on the top SNP. The top SNP in each panel is plotted as a purple upright triangle. (b) Analysis of GTExPortal CCDC170 eQTL data. Sub-panels plot either single-tissue or multi-tissue Metasoft RE2 eQTL association statistics, with the tissue or multi-tissue status labelled at the upper-right corner. Each single- or multi-tissue eQTL analysis was processed to identify putative independent signals based on pairwise EUR or AFR LD r2. SNPs in each sub-panel are colored by signal assignment and rank of the top SNPs (1st ranked = green, 2nd = orange, 3rd = purple, 4th = magenta) and sized by LD r2 to each signal’s top SNP. Inset left-side table shows GWAS/eQTL colocalization statistics: the posterior probability (PP) from the coloc Approximate Bayes Factor test (H4 ABF) and P-values for the Summary data-based Mendelian Randomization (SMR) and heterogeneity-in-dependent-instruments (HEIDI) tests. PP H4 ABF  > 0.3 and PP H4 ABF  > 0.5 were considered as nominal and moderate support of colocalization, and PP H4 ABF  > 0.9 as strong support of colocalization/pleiotropy. We considered P SMR  < 0.05 as supporting linkage/colocalization and with P HEIDI  ≥ 0.05 as strong support of pleiotropy. Main figures show representative single-tissue or multi-tissue data that had strong support for colocalization/pleiotropy (PP H4 ABF  > 0.9 | (P SMR  < 0.05 & P HEIDI  ≥ 0.05)). The top eQTL SNP in a colocalized signal is plotted as an open square. The ABF colocalization method for the current analysis was run using β-coefficients and standard errors. Coordinates and strand of genes from GENCODE V27 (bld. 37 liftover) are plotted below the mult-tissue sub-panel. The target eQTL gene is highlighted in red. (c) shows RoadMap Epigenomics epilogos plot for the 25-state imputed epigenetics segments, high LD GWAS variants (r2 equiv  > 0.8), chrom. Band, and gene transcript models.

Figure 2
Figure 2

Bust-size chr8:36.76–36.91 Mb (KCNU1/ZNF703) locus. Plot is configured the same as Fig. 1. (b) Analyses of GTExPortal eQTL data for ZNF703. Signals for ncRNA RP11-419C23.13 had strong support, but are shown in Supplementary Fig. S5. ABF colocalization analysis of multi-tissue data for both genes was run using Metasoft FE β-coefficients and standard errors as input. The gene model sub-panel highlights the two target eQTL genes in red and blue. All high LD GWAS variants shown in (c) also had RSS > 0.8 to top eQTL signal SNPs for each gene-tissue pair that is presented.

Table 2 Previously reported bust-size and dysmenorrhea-related associations.

To identify candidate causal variants underlying the two bust-size loci that were associated in our study, we performed a trans-ethnic analysis by intersecting our high LD Japanese (JPT) variants with those in high LD to the top SNPs from the Pickrell et al. report16 in 1000 G EUR (EUR) samples. We then examined eQTL and functional annotation data for those SNP sets to narrow down the candidate list.

Of 43 SNPs in high LD (r2 equiv  > 0.8) in our dataset to the chr6:151.92–151.99 Mb locus’ top variant, eighteen were also in high LD to the top Pickrell et al. SNP (rs9397437) in EUR samples. Those 18 variants also had much lower MAF in EUR compared to the other 25 SNPs (MAF~0.07 vs. MAF~0.27). All 18 SNPs were annotated by our pipeline with both estrogen receptor alpha (ESR1) and coiled-coil domain containing 170 (CCDC170) genes, but lay closer to CCDC170, with three SNPs in its 3′-UTR and the other 15 SNPs immediately downstream (Supplementary Worksheet S2; Fig. 1c). Five SNPs overlapped both Roadmap Epigenomics predicted enhancer activity23,24 and transcription factor binding sites (TFBS)25. None of the eighteen SNPs were identified as eQTLs in GTExPortal ver. 7 web-browser’s multi-tissue or single tissue data that was pre-filtered on FDR26, but we found that high LD GWAS SNPs were strongly associated with CCDC170 expression in downloaded Metasoft random-effects meta-analysis (RE2) multi-tissue eQTL statistics27,28 (Fig. 1b; top SNP rs5880935; PRE2 = 4.9 × 10−40). Within the downloaded multi-tissue data, the single tissues for which the top SNP was most strongly associated were breast mammary, subcutaneous adipose, adrenal gland, esophageal mucosa, and testis samples.

We then tested for colocalization of the bust-size and eQTL association signals using the R coloc package’s Approximate Bayes Factor (ABF) method29 as well as the Summary data-based Mendelian Randomization program SMR30. For this particular locus, for which the fixed-effects (FE) and RE2 P-values were positively correlated, we used the FE beta-coefficients and standard errors as inputs for both ABF and SMR analyses, but for other loci for which RE2 but not FE statistics were significant, we used P-values as input for the ABF method; that usage is noted in the figure legends. Examination of the locus identified the presence of multiple independent CCDC170 eQTL signals within and across different tissues, so for each successive top eQTL SNP in the multi-tissue or particular single-tissue analyses, we assigned its signal any neighbouring SNPs that were in at least nominal LD (r2 > 0.05; see Methods). To remove the impact of unlinked eQTLs on the colocalization analyses, a tested eQTL signal was examined with SNPs assigned to other eQTL signals removed. Individual eQTL signals were only tested if their moderate-highly ranked SNPs contained at least one moderate-highly ranked GWAS SNP (r2 equiv  > 0.7 & RSS > 0.7; see Methods). For testing colocalization between a GWAS and an eQTL signal, we examined the ABF posterior probability (PP H4 ABF ) and the P-values from the SMR tests of linkage (P SMR ) and heterogeneity-in-dependent-instruments test of pleiotropy (P HEIDI ); pleiotropy between GWAS and eQTL signals supports both signals as having the same underlying causal variant. We considered PP H4 ABF  > 0.3 and PP H4 ABF  > 0.5 as indicating nominal and moderate support for colocalization, respectively, while PP H4 ABF  > 0.9 provided strong support of colocalization/pleiotropy. P SMR  < 0.05 supported linkage/colocalization and with P HEIDI  ≥ 0.05, was indicative of pleiotropy between GWAS and eQTL signals. Main figures present GWAS/eQTL signals that had strong support for colocalization/pleiotropy, while the Supplementary Figures present any signals that were at least nominally colocalized (PP H4 ABF  > 0.3 | P SMR  < 0.05). Supplementary Worksheets S7 and S9 summarize nominally colocalized multi-tissue or single-tissue signals, respectively, while Supplementary Worksheets S8 and S10 show single SNP output from the ABF test for those signals.

Both ABF and SMR tests of the multi-tissue statistics strongly supported colocalization with the bust-size GWAS signal and one of the independent CCD170 multi-tissue eQTL signals (Fig. 1b lower-panel). Tests of single-tissue data supported those results but colocalization statistics provided only nominal to moderate support (Supplementary Fig. S4), except for subcutaneous adipose tissue, for which the SMR/HEIDI tests strongly supported pleitotropy (Fig. 1b upper-panel).

In the chr8:36.76–36.91 Mb locus (Supplementary Worksheet S2), we identified 17 high LD variants, of which fifteen were in very high LD with the top SNP (min. r2 ≥ 0.987) and also in high LD with the top Pickrell et al. SNP (rs10110651). The closest protein-coding gene to all fifteen variants was the potassium calcium-activated channel subfamily U member 1 gene (KCNU1), but all variants were intergenic and relatively distant from the KCNU1 gene body (>40 kb downstream). The next closest gene was the zinc finger protein 703 (ZNF703), which lies approximately 700 kb 3′- from the 15 variants. Five variants overlapped predicted epigenetic enhancer and/or bivalent-poised promoter segments in multiple tissues and several also overlapped either DNase hypersensitivity sites (DHS) defined regions of open-chromatin or TFBS (Supplementary Worksheet S2; Fig. 2c). Both ABF and SMR analyses strongly supported colocalization of the bust-size GWAS and ZNF703 eQTL signals using RE2 and single tissue data, such as breast, subcutaneous and visceral omentum adipose, and tibial nerve tissue samples (Fig. 2b), but did not identify overlap between GWAS and KCNU1 eQTLs. In addition, eQTL SNPs for the long non-coding RNA (lncRNA) RP11-419C23.1 were significantly colocalized with bust-size associated SNPs in multi-tissue and subcutaneous adipose but not breast mammary, visceral adipose, or tibial nerve tissue data (Supplementary Fig. S5). RP11-419C23.1 lay about 70 kb 3′- of the high LD GWAS SNPs, and the co-occurrence of eQTLs in subcutaneous adipose tissue samples suggests that it may act as a long-range enhancer for ZNF703 in specific tissues.

Dysmenorrhea association signals

We analyzed dysmenorrhea pain severity using a linear regression analysis after transforming the original five-level word-association scale onto an 11-point Numeric Rating Scale (NRS;; see Methods; Supplementary Fig. S6). GWAS analysis identified two strongly associated loci at chr1:115.81-115.83 Mb (Fig. 3a: top SNP: rs12030576; P = 1.13 × 10−19) and chr2:113.48–113.58 Mb (Fig. 4a: top SNP: rs80111889; P = 1.90 × 10−16), both of which were also observed for the secondary dysmenorrhea phenotypes: 1) dysmenorrhea (QOL impact) and 2) pain medicine use during menstruation (Supplementary Fig. S2; per-locus summaries: Table 2 and Supplementary Worksheet S1; per-SNP tables: Supplementary Worksheets S3, S4, and S5). In an analysis of previously reported associations, we examined genome-wide significant SNPs from two dysmenorrhea GWAS by Jones et al. in EUR samples9 and by Li et al. in Chinese samples10, and from five GWAS of endometriosis12,14,31,32,33. Of sixteen associated variants, one of two dysmenorrhea and only two out of fourteen endometriosis signals achieved an FDR < 0.1 in our analysis (Table 2; Supplementary Table S3). Notably, the recent dysmenorrhea association of rs76518691 in the ZMIZ1 gene from the Li et al. report did not replicate in our dataset10.

Figure 3
Figure 3

Dysmenorrhea (pain severity) chr1:115.80–115.83 Mb (NGF) locus. Plot is configured the same as Fig. 1. (b) shows GTExPortal lncRNA gene RP4-663N10.1 eQTL data. ABF colocalization analysis of multi-tissue data was run using Metasoft RE2 P-values as input. Candidate causal SNPs shown in (c) are SNPs with r2 equiv  > 0.8 and RSS > 0.8 to top eQTL signal SNPs for aortic artery, visceral omentum adipose, ovary, and uterus tissue samples.

Figure 4
Figure 4

Dysmenorrhea (pain severity) chr2:113.48–113.58 Mb (IL1 gene cluster) locus. Plot is configured the same as Fig. 1. (b) shows analyses of GTExPortal IL1A eQTL data. The ABF colocalization method was run using β-coefficients and standard errors. High LD GWAS/eQTL SNPs shown in (c) had r2 equiv  > 0.8 to the top GWAS SNP and RSS > 0.8 to top eQTLs in pituitary, testis, and thryoid tissues.

Chr1:115.81–115.83 Mb NGF gene region locus

The locus at chr1:115.81–115.83 Mb included 28 high LD variants around the nerve growth factor (NGF) gene, one of which was intronic and 26 of which were downstream of the NGF 3′-UTR (Supplementary Worksheet S3). Two of those SNPs replicated this recently identified locus that was reported in the Jones et al. and Li et al. dysmenorrhea GWAS analyses (rs7523086 and rs7523831, respectively; see Table 2). In GTExPortal Ver. 7 multi-tissue data, the ABF test found strong support for colocalization of the GWAS SNPs with eQTLs for RP4-663N10.1 (Fig. 3b lower panel), which is a conserved antisense lncRNA gene that spans the NGF gene. However, no significant colocalization with NGF eQTLs was identified. Both ABF and SMR tests using single-tissue data found moderate to strong support for colocalization of the dysmenorrhea signal and RP4-663N10.1 eQTLs in ovary and uterus as well as visceral omentum adipose and aortic artery single tissue data (Fig. 3b upper two panels; Supplementary Fig. S7). ABF, SMR, and HEIDI tests strongly supported pleiotropy for GWAS and eQTL signals in visceral omentum adipose tissue data. Jones et al. had previously reported the overlap of dysmenorrhea GWAS SNPs with RP4-663N10.1 eQTLs in the aortic artery tissue samples using earlier GTExPortal data, but the authors were unsure if the finding was generalizable to other tissues. Our results provide support for one or more of these SNPs regulating RP4-663N10.1 expression in multiple tissues, but interestingly, a review of the GTExPortal browser found that the direction of effect is opposite in aortic artery (and tibial artery) compared to four other GTExPortal tissues that were significant (GTEx beta-coefficients for best RE2 SNP rs7544256: βAortic artery = 0.289; βTibial artery = 0.111; βOvary = −0.413; βUterus = −0.342; βHeart-Atrial Appendage = −0.208; βVisceral Omentum adipose = −0.173). Those tissues included ovary and uterus, which we considered as more relevant to dysmenorrhea etiology than aortic artery, and in contrast to the Jones et al. conclusions, we found that alleles that increase expression of RP4-663N10.1 in the non-arterial tissues are associated with increased dysmenorrhea. In addition, while there was no data at the time of the previous publication describing the relationship between NGF and the RP4-663N10.1 lncRNA, the recently released FANTOM CAT Browser V1.0.0 identified the lncRNA34 as being significantly co-expressed with NGF (Expression Correlation = 0.4544; FDR = 1.94 × 10−92). Within RoadMap Epigenomics data, we also found that seven of the variants overlapped epigenomic marks (Supplementary Worksheet S3; Fig. 3c), with rs6657049 a likely candidate causal SNP, as it overlapped enhancer and DHS activity imputed in over twenty tissues as well as an SPI1 TFBS, and it was also predicted to modify a PU.1 (SPI1) TF motif (Supplementary Worksheet S3; HaploReg TF Motif score: REF = −2.1, ALT = 9.8).

Chr2:113.48-113.58 Mb IL1 gene cluster locus

Within the locus at chr2:113.48–113.58 Mb, we found 42 high LD variants, with all SNPs within IL1A introns or intergenic regions between IL1A and CKAP2L or IL1A and IL1B (Fig. 4a; Supplementary Worksheet S3). Some high LD SNPs (rs6542095, rs10167914) were previously found to be significantly associated with risk for endometriosis (Table 2)31,35, and one high LD SNP (rs3783550) was identified in the previous Chinese dysmenorrhea GWAS10 but did not achieve genome-wide significance in their study. A preliminary analysis of high LD SNPs for overlap with GTExPortal eQTLs found association with expression of IL1A, IL37, and IL36B, but ABF and SMR tests identified strong support for colocalization of high LD GWAS SNPs only with IL1A eQTLs (Fig. 4b); SMR and HEIDI tests in two tissues’ data supported pleiotropy (Supplementary Fig. S8). Of the 42 high LD variants, 34% (14/42) overlapped promoter, enhancer, or poised/bivalent promoter elements predicted in ≥ 20 tissues and all but one SNP also lay within TFBS (Fig. 4c; Supplementary Worksheet S3).

Menstrual fever associated chr6:154.33–154.46 OPRM1 gene region locus

Participants were queried about menstrual fever as a question about the impact/effect of fever during menstruation on their life, rather than whether the subject experienced fever during menstruation. For menstrual fever (QOL impact), we observed a nominally significant association signal at chr6:154.33–154.46 Mb (top SNP: rs17181171; P = 1.98 × 10−8) that overlaps over half of the 5′-end of the opioid receptor mu 1 (OPRM1) gene (Fig. 5a) and contains 65 high LD SNPs (Supplementary Worksheet S6). Of those variants, three variants lay in highly conserved intronic regions (rs3778146, rs3778150, rs9479759), but only two SNPs overlapped any kind of epigenomic marks, and those were both DHS without evidence of promoter or enhancer activity (Fig. 5c). However, the Epigenome browser also showed no promoter or epigenetic activity around alternative promoters or 5′-UTRs that have been described in previous reports of the OPRM1 promoter structure and regulation36,37, suggesting that the current genome-wide epigenetic datasets may be missing specific tissues needed to fully interrogate the regulatory structure of this gene. Despite the low level of regulatory annotation for associated SNPs, analysis of GWAS and multi-tissue eQTL data strongly supported pleiotropy (Fig. 5b bottom panel) and moderate to strong support was observed in single-tissue analyses (Top panels of Fig. 5b and Supplementary Fig. S9b). The alternate alleles for colocalized GWAS/eQTL SNPs had a negative effect on OPRM1 expression but a positive association with menstrual fever (Supplementary Worksheet S10).

Figure 5
Figure 5

Menstrual fever (QOL impact) chr6:154.33–154.46 Mb (OPRM1) locus. Plot is configured the same as Fig. 1. (b) shows analyses of GTExPortal OPRM1 eQTL data. The ABF colocalization method was run using β-coefficients and standard errors. Candidate causal SNPs shown in (c) are SNPs with r2 equiv  > 0.8 and RSS > 0.8 to top eQTL signal SNPs for brain cerebellar hemisphere and testis tissue samples.


In this study, we performed a meta-analysis of two independent GWAS cohorts to identify loci associated with genetic susceptibility to gynecologic phenotypes in the Japanese population. From this analysis of 22 trait variables, we identified loci that influence bust size, severity of dysmenorrhea, and menstrual fever.

Bust-size associated loci

To better understand the overlap of bust-size associated signals between different ethnic populations, we examined whether SNPs previously associated with either bust-size15,16 or with the related phenotype of mammographic density15,16,21 could be replicated in our dataset and found that 33% of top SNPs (6/18) that were polymorphic in JPT could be replicated in our data at an FDR < 0.1 (for FDR < 0.2: 50% = 9/18 replicated). As a caveat for that analysis, we note that in examining the associated genes listed in Pickrell et al., one of their loci is annotated with the FTO gene, which has known associations with BMI38,39,40. Since we adjusted for BMI in order to find genes that increase bust-size irrespective of increased BMI, some of the Pickrell associations may be capturing increases in bust-size related to BMI rather than non-adiposity related associations. That may also be reflected in the higher replication rate for SNPs that were previously associated with both breast-size and mammographic density as well as SNPs identified in the Eriksson et al. study, which adjusted their regression using a surrogate measure for BMI (Supplementary Table S2; Eriksson et al. 4/5 SNPs replicated with FDR < 0.2).

Our analysis of bust-size in the Japanese population identified two significant loci, one of which colocalizes with CCDC170 and the other which lay between KCNU1 and ZNF703. As noted in Table 2, those two loci were among those identified in the Eriksson et al. and Pickrell et al. studies15,16. The Eriksson et al. report also found overlap between breast-size associated SNPs and/or gene regions with previous associations for breast cancer susceptibility21,41,42,43,44,45.

CCDC170, which is located adjacent to the ESR1 gene, was recently shown by Jiang et al. to function in the organization and stability of microtubules that associate with the Golgi apparatus, and also, that it plays a role in polarized cell migration46. Interestingly, we found that CCDC170 was expressed most highly across reproductive (ovary, testis, cervix, fallopian tubes, breast) and glandular (adrenal gland, thyroid, subcutaneous adipose) GTExPortal Ver. 7 tissue samples, suggesting that it may play a role in tissue development and remodeling relatively specific to such tissues. In terms of disease and other phenotypic associations, ESR1-CCDC170 rearrangements have been characterized in an aggressive type of ER positive breast cancer47, and the CCDC170-ESR1 locus was also reported to be associated with bone mineral density48,49, which was reduced by loss-of-function mutations in the human ESR1 gene50. Certain of the bust-size associated variants near the 3′- end of CCDC170 identified in this and previous reports (Table 2)15,16 have also been associated with spinal bone mineral density (rs6929137)51 and breast cancer in Chinese (rs2046210)41, and it was recently proposed that these variants reflect regulatory elements relevant to ESR1 expression52. However, both our analysis of GTEx eQTL data and that shown by the recent Bailey et al. report found scant evidence that these SNPs were associated with ESR1 expression. In contrast, our current eQTL analysis of breast mammary tissue found that these variants are much more strongly associated with expression of CCDC170 than ESR1. In addition, while Bailey et al. identified chromosomal interactions between the region around the high LD SNPs and the promoter of ESR1, their data also showed interactions with the promoter region of CCDC170 (Bailey et al. Fig. 2a52). Also, in identifying the function of CCDC170, the recent Jiang et al. report46 concluded from Differential Allele Specific Expression analysis in human mammary epithelial cell lines that previously reported breast cancer associated SNPs in this locus were driven by regulation of CCDC170 rather than of ESR1. Finally, a recent Japanese study replicated the Chinese breast cancer association and showed that CCDC170 gene expression was inversely correlated with estrogen receptor positivity53, suggesting that there may exist regulatory interplay between the two genes and their regulatory elements.

For the other bust-size association signal at chr8:36.76–36.91 Mb, all associated variants resided in an intergenic region between the two protein-coding genes KCNU1 and ZNF703. GTExPortal Ver. 7 data showed that the top SNPs are associated with expression of both ZNF703 and the lncRNA RP11-419C23.1 in subcutaneous adipose tissue samples, despite the two genes being over 700 kb from each other, suggestive of the lncRNA acting as a long-range enhancer in the regulation of ZNF703 expression. ZNF703 is a member of the NET zinc finger protein family, and along with its paralogue ZNF503, is conserved throughout almost all vertebrate species54. ZNF703 has been shown to mainly act as a transcriptional repressor and to play a role during embryogenesis55. Additionally, ZNF703 is in a long-investigated region that is often amplified in a subset of breast cancers and through investigation of expression, narrowing the consensus region of amplification56, and in vitro experiments in mouse mammary tissue57,58, the causal oncogene in this region is thought to be the ZNF703 gene. Based on our GWAS results and the GTExPortal data, the effect (minor) allele at associated variants correlates with both reduced ZNF703 expression in breast mammary tissue and decreased bust-size (Supplementary Worksheet S9 and S10). Those results agree with reported in vitro experiments in non-malignant human mammary epithelial cells (HMEC) which showed that overexpression of ZNF703 increased cell proliferation59.

Dysmenorrhea associated loci

Dysmenorrhea is the most common gynecological disorder among women of reproductive age, which negatively impacts quality of life and work productivity. The prevalence of dysmenorrhea varies between 16 and 91% of menstruating women60. According to epidemiologic studies, dysmenorrhea was reported to be positively related with family history of the disorder5,6. In this study, we identified two associated loci, which colocalize with NGF and the IL1 gene locus.

The GWAS locus identified in the NGF gene region on chromosome 1 overlaps potential regulatory regions and is associated with expression of an antisense gene that spans the NGF locus. In line with our study, a previous GWAS study in a European ancestry population identified high LD SNPs in potential regulatory regions of NGF and the lncRNA RP4-663N10.1 that overlaps NGF9, and a recent study in a Chinese population sample also identified this signal10. As such, the current report serves as a trans-ethnic replication of those recent findings. NGF is a neurotrophic molecule, which regulates the structure and function of sensory and sympathetic neurons61,62. In addition, the role of NGF as an important mediator of pain is supported by superior pain relief in clinical trials using Tanezumab, a monoclonal antibody that inhibits NGF, for the treatment of osteoarthritis and lower back pain63,64,65. Considering that evidence, NGF may be a plausible causal gene of dysmenorrhea, although we found no direct correlation between our identified SNPs and NGF expression. However, we did identify the SNPs as eQTLS for RP4-663N10.1, and FANTOM CAT Browser data identified very significant co-expression between that lncRNA and NGF, suggesting that RP4-663N10.1 plays a role in regulating NGF levels.

The IL1 gene locus includes the IL1A and IL1B genes, which encode pro-inflammatory cytokines (IL-1alpha and IL-1beta) that share the same receptors, but are expressed in different tissue types (IL1A: epithelial layers of lung, gastroentestinal tract, liver, kidney, endothelial cells; IL1B: hematopoetic cells like skin dendritic cells, monocytes, macrophages, etc.) and have different modes of activity (IL1A: fully active upon secretion; IL1B: requires cleavage by processed Caspase-1)66. These cytokines were reported to be the key factor of PGE2 and PGF2a production in uterine myometrial cells67,68,69, and the overproduction of uterine prostaglandins has been a widely accepted explanation for the pathophysiology of dysmenorrhea70,71. The most common and effective medical treatment for dysmenorrhea are non-steroidal anti-inflammatory drugs (NSAIDs), which are prostaglandin synthetase inhibitors. Considering that, the inflammatory responses induced by the IL-1 cytokine family have been suggested to be associated with dysmenorrhea.

Multiple GWAS studies in Japanese and European population samples have identified the IL1A gene locus as associated with endometriosis, which was the most common pathological condition related to secondary dysmenorrhea11,13,72. Primary dysmenorrhea was also reported to be associated with subsequent development of endometriosis in an epidemiological case-control study3. The recent Li et al. Chinese GWAS also identified IL1A as associated with dysmenorrhea, but the results were based on gene-based and pathway analysis, and IL1A variants did not achieve genome-wide significance. Since the SNPs identified in the earlier GWAS reports of endometriosis and dysmenorrhea are in LD with and appear to represent the same signal as those in our current study, our analysis of epigenetic functionality and eQTLs provides insight into the genetic relationship between dysmenorrhea and the development of endometriosis in terms of linked SNPs and gene expression in the IL1 gene region.

Menstrual fever associated locus

A slight increase in body temperature (0.3–0.5 degrees C) can occur from day 15 to day 25 of a normal 28-day menstrual cycle, but for some women, a greater temperature increase can occur, although it is generally not considered to be pathologic in nature73. Over seventy years ago, Reimann termed this “habitual hyperthermia“74, and since then, there have been limited case study reports for some extreme instances of menstrual cycle-dependent febrile episodes75,76,77,78, but to our knowledge, there is no epidemiological report about its frequency and clinical significance. In the current study, the frequencies of subjects reporting QOL impact by menstrual fever was 1.95% (112/5734, LL01) and 2.80% (157/5614, LL02) in the two study stages.

For menstrual fever, the single nominally significant genetic association was in a region that contains the OPRM1 gene, which encodes μ-opioid receptor (MOR), which binds endogenous opioids such as β-endorphin and endomorphin. The top SNPs resided either in the region upstream of or within the first intron of two transcripts that encode MOR-1K (Fig. 5c; Ensembl transcript IDs: ENST00000522555 and ENST00000522236), which is a truncated six-transmembrane domain MOR isoform (6TM-MOR) that is missing the extracellular N-terminal domain as well as the first transmembrane domain present in the seven-transmembrane MOR (7TM-MOR)37. Upon opioid stimulation, 6TM-MOR has been reported to exhibit excitatory effects instead of the inhibitory effects expected of 7TM-MOR, leading to increased Ca2+ and release of nitrous oxide (NO)79. Previous reports in animal models have shown that β-endorphin plays a role in management of body temperature (Tb), with administration of β-endorphin into the pre-optic/anterior hypothalamus (POAH) of rabbits resulting in vasoconstriction, decline in evaporative heat loss, and an increase in Tb80, while in Syrian hamsters, experimental analyses suggested that β-endorphin produced in the arcuate nucleus plays a role in regulating Tb during hibernation by activating MOR in several regions of the hypothalamus81. Additionally, the Gordon et al. rabbit report suggested that β-endorphin injection did not actually cause fever, since it did not increase the metabolic rate, but rather appeared to lead to hyperthermia by modifying POAH neuronal sensitivity to external temperature.

Potentially, since altered temperature perception (hot/cold flashes) is a symptom of opiate withdrawal82, and endogenous opioids act in the analgesia of pain control83, decreased expression of OPRM1 in the context of menstrual pain response may elicit symptoms similar to opiate withdrawal in subjects. To examine whether this possibility was supported by our data, we examined the number of fever cases and controls with respect to the transformed Dysmenorrhea pain scores. Over three times as many subjects with the highest Dysmenorrhea score reported QOL impacted by menstrual fever as those with the four lower Dysmenorrhea scores (3.97% vs. 1.27%). In a logistic regression analysis of menstrual fever in low and high pain score groups (low pain scores 0, 1, 2, 5 vs. high score of 10), the low score group was only nominally significant at P = 0.01679 versus P = 1.74 × 10−6 in high pain score subjects. Further analyses will be required to confirm the association of OPRM1 variants with menstrual fever in other population samples and to explore the role that these SNPs play in regulating expression of MOR isoforms.


In this study, we performed GWAS analyses for a large number of gynecology related traits in over eleven-thousand Japanese female subjects. For bust-size analyses, we identified two significant loci and were able to show that about one-third of previously identified associations discovered in EUR samples replicate in Japanese. Similarly, we were able to replicate a recent finding in EUR and Chinese samples for dysmenorrhea pain severity in the NGF gene locus, and we further identified a novel dysmenorrhea association in the IL1 gene locus that is in LD with known endometriosis associated variants. Moreover, we identified candidate causal variants for dysmenorrhea that likely regulate expression of IL1A. Finally, in the OPRM1 gene, we identified a novel association for menstruation associated fever that will require further analyses to better understand in terms of its broader applicability and biological under-pinnings.

This GWAS supports the benefits of analyses of diverse phenotypes in different ethnic population samples and showed the benefits of using eQTL datasets made up of diverse tissue types. Using GWAS/eQTL colocalization analysis with the latest GTExPortal dataset, we were able to show that the top GWAS SNPs in each of the loci identified in this study were also associated with expression of a protein-coding and/or a lncRNA gene. Further research will be needed to further elucidate how these eQTLs influence human phenotypic variation.


Subject, sample, and phenotype data collection

The MTI subsidiary EverGene developed a study to investigate the genetics of certain human traits. Study subjects were collected by soliciting users of MTI’s ( “Luna Luna” women’s healthcare-related information website and apps to voluntarily participate, with sample collection performed in two stages, denoted as LL01 and LL02. Survey Monkey ( was used to create questionnaires to solicite trait information and then filled-out by subjects online. DNA was obtained using saliva sampling kits (OraGene; DNA Genotek, Inc., Ottawa, Canada). In total, we obtained saliva samples and questionnaire data from 11379 female participants (LL01 = 5751, LL02 = 5628). The study design, including the consent form, general questionnaire topics, and genotyping, was approved by the Institutional Review Board at the Tsukuba International Clinical Pharmacology Clinic. The study was performed in accordance with applicable regulations and guidelines, and written informed consent was obtained from each patient for sample collection, genotyping, trait questionnaire, and trait analysis using genome-wide association study analysis.

Sample processing, genotyping and quality control

Saliva sample kits were processed by Takara Bio (Kusatsu, Shiga Prefecture, Japan). LL01 and LL02 stage sample plates were genotyped separately for each stage by Takara Bio on a custom East Asian specific Axiom array (EverGene1). The EverGene1 chip contains 607857 total variants, with most variants chosen from Axiom CHB-1 chip SNPs that had MAF ≥ 0.01 in 1000 Genomes Project Japanese ancestry samples and additional custom variants selected from those with known pathogenic or phenotypic associations. Each stage’s genotypes were divided into separate batches and called separately using Affymetrix Analysis Suite 1.1.0616. There were 329 duplicate samples that we used to calculate genotype concordance between the two stages for each SNP. For downstream analyses, we only included autosomal and chromosome X variants that fulfilled the following criteria in both stages: 1) ≥ 99% call-rate, 2) MAF ≥ 0.01, 3) HWE P-value ≥ 1 × 10−6, and 4) concordance-rate > 90%. After applying those filters, there were 536506 variants, of which 2417 were insertion-deletion polymorphisms (INDEL). Across those QC + variants, the average concordance-rate was 99.85 ± 0.30% (mean ± SD).

Principal component analysis (PCA)

We downloaded genotype data for 2504 samples from the 1000 Genomes Project Phase 317,84, sample populations ( to help identify any admixed samples in our Japanese sample dataset. We then performed LD-pruning across the 1000 Genomes and LL01 and LL02 (LL01/LL02) genotype datasets using PLINK2 v1.90p (release date 16 Aug 2016)85,86 with r2 < 0.2, which identified 121595 SNPs with no or low-LD. We performed a principal component analysis (PCA)87 using PLINK with the LD-pruned SNPs, and after one round of PCA, a small number of samples were identified as outliers (n = 19) to the typically recognized East Asian cluster88,89. Overlap with other populations suggested some level of admixture with European, African, or South Asian ancestry. To reduce downstream biases, we removed the admixed samples and performed a second round of PCA with LL01/LL02 + 1000 G EAS samples to help identify overlap of clustered samples with known East Asian sub-groups. After that, we performed a third round of PCA with just those LL01/LL02 samples so that the top PCs would reflect the main genetic axes of East Asian and Japanese population structure inherent to our population samples. A figure showing results from those different PCA steps can be viewed as Supplementary Fig. S1 in the recent Khor SS, et al. report that used the same MTI/EverGene sampleset90.

Identification of duplicated samples

Using the same LD-pruned SNP data, we performed identify-by-descent (IBD) analysis using PLINK2 ver. 1.90p’s to identify potential duplicated samples. From eleven sample pairs with close relatedness (PI_HAT > 0.8), we removed one sample from each pair from downstream analyses.

Definition of gynecology-related phenotypes

For the bust-size analysis, bra-size was coded on a 0 to 7 scale (AA = 0, A = 1, B = 2, C = 3, D = 4, E = 5, F = 6, ≥ G = 7). Dysmenorrhea pain severity was originally queried in Japanese using a five-level word-association scale with 1 = not at all painful, 2 = not very painful, 3 = neither painful or unpainful, 4 = slightly painful, and 5 = very painful; (Closest English translations). We examined correlation between these arbitrary integer levels and the proportion of participants within each level who used pain medicine during menstruation and found that pain medicine use increased exponentially with severity levels (Supplementary Fig. S6a). As that suggested that the distance between queried pain severity levels was not equidistant, we considered that using untransformed values in a linear regression would have less power to detect an association. Therefore, we transformed the integer values by mapping them into an 11-point Numeric Rating Scale (NRS; which can be sub-divided into ranges with 0 = No pain, 1–3 = Mild Pain, 4–6 = Moderate Pain, and 7–10 = Severe Pain. We mapped our five-levels to the NRS as 1-> 0 (No pain), 2-> 1 (Mild pain), 3-> 2 (Mild pain), 4-> 5 (Moderate pain), and 5-> 10 (Severe pain). Supplementary Fig. S6 shows that this mapping effectively linearizes the relationship between pain severity and another related variable, the proportion of individuals within each level that reported pain medicine use in our dataset. Dysmenorrhea (QOL impact) and menstrual fever (QOL impact) were queried to participants as whether during menstruation these symptoms had an effect on their life, and menstrual pain medicine use was asked in a questionnaire section on use of various medications that a participant often used. Those answering affirmatively were considered cases and those without affirmative answers considered as controls.

Statistical analysis and genotype imputation

We used R 3.4.1 statistical environment for data management, statistical analyses, and figure plotting92. We performed the primary association analysis using PLINK2′s linear or logistic regression analysis methods. For each phenotype analyzed, we included PC1 and PC2 (from the the stage 3 PCA described above) as covariates, and then BMI or Age included as additional covariates if they were significantly correlated with the phenotype in a regression analysis (P < 0.05). The meta-analysis P-value was calculated using a fixed-effects method with inverse variance weighting. We extracted the effective number of SNPs (ME) for a platform of a similar size and the JPT population from a study of different genotyping platforms18, for a single GWAS P-value cut-off of 1.21 × 10−7 (0.05/411,521). Signals with more than one genotyped SNP achieving that cutoff were defined as nominally associated, and based on the number of phenotypes analysed in this analysis, we defined strongly associated signals as those that achieved a multiple-testing adjusted P-value cut-off of P < 5.5 × 10−9 (P < 1.21 × 10−7/22 female-related phenotypes).

For comparison with previous reports and for Manhattan plots, we performed genome-wide imputation based on summary statistics using the program DISTMIX22 with 1000 Genomes Project Phase 1 Release 3 reference data. Genotype-based imputation was performed only for regions surrounding associated variants by first pre-phasing the LL01/LL02 genotyping dataset using EAGLE 293,94 and then imputing missing variants using BEAGLE 4.195 with the 1000 G Phase 3 reference haplotypes96. We imputed SNPs within 2 Mb of each association signal and then performed linear or logistic regression analysis conditioning on the top imputed variant to better understand the structure of the association signal and identify un-genotyped top associated variants in each signal that could be candidate causal variants.

Measures of LD

Using PLINK 1.9, we calculated the traditional LD r2 and D’ measures using the imputed genotype data. As an alternative measure, we also calculated what we term r2 equiv , which uses conditional regression analysis to measure the decrease of the signal at a SNP B relative to a top SNP A. Briefly, considering a test statistic labeled Z (typically, chi-square statistic), with Z A the unadjusted statistic at SNP A, Z B the unadjusted statistic at SNP B, and Z B|A the statistic at SNP B conditioned on SNP A, then r2 equiv was calculated as r2 equiv  = (Z B  − ZB|A)/Z A .

In silico functional analysis of associated variants

For analyses using rsIDs, we strived to use the then current dbSNP147 rsID wherever possible. Using R scripts, we imported the RsMergeArch.bcp.gz table from NCBI’s ftp site and identified the current rsID for SNPs present in the various annotation sources used below.

We annotated genotyped and 1000 G variants using HaploReg 4.197, which includes regulatory annotation for transcription factor (TF) motif changing SNPs, DNase hypersensitivity sites (DHS), DNA methylation, evolutionary conservation scores (GERP and SiPhy), gene overlap, eQTLs, and known reported associations from the Genome-Wide Repository of Associations Between SNPs and Phenotypes (GRASP)98,99. Since HaploReg and 1000 G used different dbSNP versions, we identified both the current rsID and all previously used rsIDs for each SNP, passed all rsIDs to HaploReg for annotation, and then processed the output to resolve the current rsID with the one actually used by HaploReg. To examine overlap with experimentally determine TF binding sites (TFBS), we annotated a bed file of our variant positions using the ReMap (“An integrative ChIP-seq analysis of regulatory elements”) web-site’s annotation tool ( and summarized the number of TFBS genes intersecting each variant.

For gene annotation, from the UCSC Genome Browser web-site we downloaded two files (wgEncodeGencodeBasicV24lift37.txt.gz, wgEncodeGencodeAttrsV24lift37.txt.gz) that contained GENCODE v.24 gene information that had been lifted over from GRCh38/hg20 to GRCh37/hg19 human genome build coordinates. For SNP annotation, we processed those files to extract the strand and transcript start and stop sites for 19761 protein-coding, 5577 antisense, 7705 lincRNA, and 3042 miRNA genes present on chromosomes 1–22 and chromosome X. Overlap of gene and SNP coordinates was performed using the R Bioconductor GenomicRanges packages. We labeled SNPs with four categories of genic overlap/nearness: 1) “within” = SNP between start and stop coordinates of a gene’s coding region, 2) “upstream” = SNP < 100 kb upstream of the gene start position, 3) “downstream” = SNP < 40 kb downstream of the gene stop position, 4) “closest” = for SNPs with no genes fulfilling the first three rules, we picked the closest gene to the SNP. “Closest” gene is not provided as a separate column, but listed in a column “Genes (all)” that either contains the union of within/upstream/downstream genes for a SNP, or if those are missing, contains the closest gene. The 100 kb upstream and 40 kb downstream cutoffs were chosen based on previous reports that analyzed the general distance from Transcription Start Site (TSS) and Transcription End Site (TES) within which most eQTL SNPs are identified100,101.

A current version of the NHGRI/EBI GWAS Catalog ( was downloaded on February 6, 2018 from the UCSC Genome Browser103 and used for annotation of SNPs for previous GWAS results.

For preleminary examination of GTExPortal eQTL data, we downloaded GTEx_Analysis_v7_eQTL.tar from the GTExPortal web-site104 and imported the *signif_variant_gene_pairs.txt and *egenes.txt tables into R. To annotate eQTL tables with rsids, positions, etc. we merged them with data in GTEx_Analysis_2016-01-15_v7_WholeGenomeSeq_635Ind_PASS_AB02_GQ20_HETX_MISS15_PLINKQC.lookup_table.txt.gz and for gene information, we used data in the file gencode.v19.genes.v7.patched_contigs.gtf. For annotation of GWAS SNPs, we downloaded the multi-tissue eQTL data file GTEx_Analysis_v7_eQTL.tar.gz and imported the table into R for analysis. For each SNP in Supplementary Worksheets S2S6, we summarized the minimum P-value across all genes from each of the multi-tissue analysis’s27 fixed-effects (FE), random-effects (RE), and Metasoft random-effects (RE2)28 columns. The table’s single-tissue P-value columns were reshaped for aggregation and summarizing value. For each SNP:gene pair, we calculated the minimum P-value across the single-tissue P-values and also an FDR across tissues that had non-missing P-values. The eQTL column in Supplementary Worksheets S2S6 presents a formatted string for each SNP for Tissue:Gene:P-value combinations that achieved FDR < 0.1. For certain tissues used in specific analyses for which we needed complete unfiltered data, we downloaded individual “all pairs” files from the GTEx dataset URL ( listed under the “Tissue-Specific All SNP Gene Associations” sub-heading.

GWAS/eQTL colocalization analysis

We performed formal tests for colocalization of GWAS and GTEx eQTL association signals using the Approximate Bayes Factor (ABF) method in the R coloc (ver. 2.3–7) package’s coloc.abf function29 as well as the Summary data-based Mendelian Randomization method used in the SMR program (ver 0.702) available on the CNS Genomics web-site ( Analysis was performed using either GTEx multi-tissue meta-analysis statistics or the unfiltered single-tissue data. For ordering and filtering linked SNPs in an eQTL signal, we calculated what we term Relative Signal Strength (RSS) using the absolute values of Z-score statistics for a linked SNP B and top eQTL A as RSS B|A  = Z B /Z A .

Since eQTL data for certain genes suggested the presence of multiple independent signals, we first parsed a gene’s single-tissue or multi-tissue data at a particular locus into groups of SNPs that were in LD to a particular unlinked top eQTL variant. Briefly, a gene’s eQTL data was sorted by association statistics, and SNPs that had LD r2 > 0.05 to the top unlinked SNP were assigned to that SNP. LD was calculated using PLINK2 across either EUR or AFR samples’ data from 1000 Genomes Project Phase 3, and we then assigned the maximum value across EUR or AFR samples. For a small number of signals, nominally linked SNPs had stronger association statistics than one might expect based on r2 to a particular top SNP. In such instances, we examined the ratio of RSS to r2 and left such SNPs unassigned to a top SNP if the value was large (i.e. RSS/r2 > 3, >5, >10), after which they they could be searched further for additional independent signals.

For both ABF and SMR analyses of single-tissue data, we used the beta-coefficients and standard errors from the GWAS and eQTL regression analyses as input. For multi-tissue eQTL signals, Metasoft RE2 statistics appeared to be more powerful than traditional FE or RE analyses for identifying eQTLs that act across multiple tissues, but the nature of the RE2 data meant that there were not traditional beta-coefficients and standard errors available to use as input. Therefore, for eQTL signals for which the absolute value of multi-tissue association Z-scores (abs(Z FE ), abs(ZRE2)) were positively correlated (Pearson’s product-moment correlation coefficient r > 0.8), we used the FE beta and SE as input for both ABF and SMR analysis, but for signals for which they were not strongly correlated, we ran the ABF analysis using the RE2 P-values along with required MAF and sample-size values. Note that in that case, SMR results using the FE statistics would differ from those from ABF. Since GTEx eQTL analyses were performed using standardized expression values, we used a value of 1.0 for the standard deviation of expression trait values in the analysis using coloc.abf.

Figure plotting

Self-written R programs were used to produce many figures, with others done using outside software/web-services. Epigenetic state plots were made using RoadMap Epigenomics data from the Washington University Epigenome Browser ( and their publication quality image “Screenshot” function. GENCODE V19106 was used to plot gene transcript models. Custom tracks for top SNPs in association signals were plotted from uploaded BED files. The imputed 25-state model from the RoadMap Epigenomics Project is plotted as an epilogos visualization. The Epilogos custom track: GTExPortal ( plotting functions were used to make figures of GTEx Project gene expression and eQTL data.

Data availibility

Due to a concern for subject privacy and restrictions in the the study consent form, the genotype data for this study is not publicly available to outside researchers. However, we do make the genome-wide summary statistics (β-coefficient and SE, P-value, effect-allele frequency) available in the Supplementary Information as Supplementary Datasets S1S22.

Additional information

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


  1. 1.

    Kusano, A. S. et al. A prospective study of breast size and premenopausal breast cancer incidence. Int J Cancer 118, 2031–2034 (2006).

  2. 2.

    Ray, J. G., Mohllajee, A. P., van Dam, R. M. & Michels, K. B. Breast size and risk of type 2 diabetes mellitus. CMAJ 178, 289–295 (2008).

  3. 3.

    Treloar, S. A., Bell, T. A., Nagle, C. M., Purdie, D. M. & Green, A. C. Early menstrual characteristics associated with subsequent diagnosis of endometriosis. Am J Obstet Gynecol 202, 534.e1–6 (2010).

  4. 4.

    Chapron, C. et al. Questioning patients about their adolescent history can identify markers associated with deep infiltrating endometriosis. Fertil Steril 95, 877–881 (2011).

  5. 5.

    Tavallaee, M., Joffres, M. R., Corber, S. J., Bayanzadeh, M. & Rad, M. M. The prevalence of menstrual pain and associated risk factors among Iranian women. J Obstet Gynaecol Res 37, 442–451 (2011).

  6. 6.

    Ozerdogan, N., Sayiner, D., Ayranci, U., Unsal, A. & Giray, S. Prevalence and predictors of dysmenorrhea among students at a university in Turkey. Int J Gynaecol Obstet 107, 39–43 (2009).

  7. 7.

    He, C. & Murabito, J. M. Genome-wide association studies of age at menarche and age at natural menopause. Mol Cell Endocrinol 382, 767–779 (2014).

  8. 8.

    Demerath, E. W. et al. Genome-wide association study of age at menarche in African-American women. Hum Mol Genet 22, 3329–3346 (2013).

  9. 9.

    Jones, A. V. et al. Genome-wide association analysis of pain severity in dysmenorrhea identifies association at chromosome 1p13.2, near the nerve growth factor locus. Pain 157, 2571–2581 (2016).

  10. 10.

    Li, Z. et al. Common variants in ZMIZ1 and near NGF confer risk for primary dysmenorrhoea. Nat Commun 8, 14900 (2017).

  11. 11.

    Sapkota, Y. et al. Independent Replication and Meta-Analysis for Endometriosis Risk Loci. Twin Res Hum Genet 18, 518–525 (2015).

  12. 12.

    Nyholt, D. R. et al. Genome-wide association meta-analysis identifies new endometriosis risk loci. Nat Genet 44, 1355–1359 (2012).

  13. 13.

    Adachi, S. et al. Meta-analysis of genome-wide association scans for genetic susceptibility to endometriosis in Japanese population. J Hum Genet 55, 816–821 (2010).

  14. 14.

    Uno, S. et al. A genome-wide association study identifies genetic variants in the CDKN2BAS locus associated with endometriosis in Japanese. Nat Genet 42, 707–710 (2010).

  15. 15.

    Eriksson, N. et al. Genetic variants associated with breast size also influence breast cancer risk. BMC Med Genet 13, 53 (2012).

  16. 16.

    Pickrell, J. K. et al. Detection and interpretation of shared genetic influences on 42 human traits. Nat Genet 48, 709–717 (2016).

  17. 17.

    Auton, A. et al. A global reference for human genetic variation. Nature 526, 68–74 (2015).

  18. 18.

    Li, M. X., Yeung, J. M., Cherny, S. S. & Sham, P. C. Evaluating the effective numbers of independent tests and significant p-value thresholds in commercial genotyping arrays and public imputation reference datasets. Hum Genet 131, 747–756 (2012).

  19. 19.

    Burdett, T. et al. The NHGRI-EBI Catalog of published genome-wide association studies. (Accessed February 2, 2017).

  20. 20.

    MacArthur, J. et al. The new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog). Nucleic Acids Res 45, D896–D901 (2017).

  21. 21.

    Lindström, S. et al. Genome-wide association study identifies multiple loci associated with both mammographic density and breast cancer risk. Nat Commun 5, 5303 (2014).

  22. 22.

    Lee, D. et al. DISTMIX: direct imputation of summary statistics for unmeasured SNPs from mixed ethnicity cohorts. Bioinformatics 31, 3099–3104 (2015).

  23. 23.

    Zhou, X. et al. Epigenomic annotation of genetic variants using the Roadmap Epigenome Browser. Nat Biotechnol 33, 345–346 (2015).

  24. 24.

    Kundaje, A. et al. Integrative analysis of 111 reference human epigenomes. Nature 518, 317–330 (2015).

  25. 25.

    Griffon, A. et al. Integrative analysis of public ChIP-seq experiments reveals a complex multi-cell regulatory landscape. Nucleic Acids Res 43, e27 (2015).

  26. 26.

    Consortium, G. T. E. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science 348, 648–660 (2015).

  27. 27.

    Sul, J. H., Han, B., Ye, C., Choi, T. & Eskin, E. Effectively identifying eQTLs from multiple tissues by combining mixed model and meta-analytic approaches. PLoS Genet 9, e1003491 (2013).

  28. 28.

    Han, B. & Eskin, E. Random-effects model aimed at discovering associations in meta-analysis of genome-wide association studies. Am J Hum Genet 88, 586–598 (2011).

  29. 29.

    Giambartolomei, C. et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet 10, e1004383 (2014).

  30. 30.

    Zhu, Z. et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. Nat Genet 48, 481–487 (2016).

  31. 31.

    Sapkota, Y. et al. Meta-analysis identifies five novel loci associated with endometriosis highlighting key genes involved in hormone metabolism. Nat Commun 8, 15539 (2017).

  32. 32.

    Wang, W. et al. Pooling-Based Genome-Wide Association Study Identifies Risk Loci in the Pathogenesis of Ovarian Endometrioma in Chinese Han Women. Reprod Sci 24, 400–406 (2017).

  33. 33.

    Uimari, O. et al. Genome-wide genetic analyses highlight mitogen-activated protein kinase (MAPK) signaling in the pathogenesis of endometriosis. Hum Reprod 32, 780–793 (2017).

  34. 34.

    FANTOM CAT Browser. (September 27, 2107).

  35. 35.

    Sapkota, Y. et al. Association between endometriosis and the interleukin 1A (IL1A) locus. Hum Reprod 30, 239–248 (2015).

  36. 36.

    Pan, Y. X. Diversity and complexity of the mu opioid receptor gene: alternative pre-mRNA splicing and promoters. DNA Cell Biol 24, 736–750 (2005).

  37. 37.

    Pasternak, G. W. & Pan, Y. X. Mu opioids and their receptors: evolution of a concept. Pharmacol Rev 65, 1257–1317 (2013).

  38. 38.

    Hotta, K. et al. Variations in the FTO gene are associated with severe obesity in the Japanese. J Hum Genet 53, 546–553 (2008).

  39. 39.

    Willer, C. J. et al. Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet 41, 25–34 (2009).

  40. 40.

    Yang, J. et al. FTO genotype is associated with phenotypic variability of body mass index. Nature 490, 267–272 (2012).

  41. 41.

    Zheng, W. et al. Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat Genet 41, 324–328 (2009).

  42. 42.

    Fletcher, O. et al. Novel breast cancer susceptibility locus at 9q31.2: results of a genome-wide association study. J Natl Cancer Inst 103, 425–435 (2011).

  43. 43.

    Couch, F. J. et al. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet 9, e1003212 (2013).

  44. 44.

    Garcia-Closas, M. et al. Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet 45(392-8), 398e1 (2013).

  45. 45.

    Long, J. et al. Genome-wide association study in east Asians identifies novel susceptibility loci for breast cancer. PLoS Genet 8, e1002532 (2012).

  46. 46.

    Jiang, P. et al. The Protein Encoded by the CCDC170 Breast Cancer Gene Functions to Organize the Golgi-Microtubule Network. EBioMedicine 22, 28–43 (2017).

  47. 47.

    Veeraraghavan, J. et al. Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers. Nat Commun 5, 4577 (2014).

  48. 48.

    Mullin, B. H. et al. Genome-wide association study using family-based cohorts identifies the WLS and CCDC170/ESR1 loci as associated with bone mineral density. BMC Genomics 17, 136 (2016).

  49. 49.

    Estrada, K. et al. Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet 44, 491–501 (2012).

  50. 50.

    Smith, E. P. et al. Impact on bone of an estrogen receptor-alpha gene loss of function mutation. J Clin Endocrinol Metab 93, 3088–3096 (2008).

  51. 51.

    Styrkarsdottir, U. et al. New sequence variants associated with bone mineral density. Nat Genet 41, 15–17 (2009).

  52. 52.

    Bailey, S. D. et al. Noncoding somatic and inherited single-nucleotide variants converge to promote ESR1 expression in breast cancer. Nat Genet 48, 1260–1266 (2016).

  53. 53.

    Yamamoto-Ibusuki, M. et al. C6ORF97-ESR1 breast cancer susceptibility locus: influence on progression and survival in breast cancer patients. Eur J Hum Genet 23, 949–956 (2015).

  54. 54.

    Pereira, F., Duarte-Pereira, S., Silva, R. M., da Costa, L. T. & Pereira-Castro, I. Evolution of the NET (NocA, Nlz, Elbow, TLP-1) protein family in metazoans: insights from expression data and phylogenetic analysis. Sci Rep 6, 38383 (2016).

  55. 55.

    Nakamura, M., Choe, S. K., Runko, A. P., Gardner, P. D. & Sagerström, C. G. Nlz1/Znf703 acts as a repressor of transcription. BMC Dev Biol 8, 108 (2008).

  56. 56.

    Melchor, L. et al. Genomic analysis of the 8p11-12 amplicon in familial breast cancer. Int J Cancer 120, 714–717 (2007).

  57. 57.

    Slorach, E. M., Chou, J. & Werb, Z. Zeppo1 is a novel metastasis promoter that represses E-cadherin expression and regulates p120-catenin isoform expression and localization. Genes Dev 25, 471–484 (2011).

  58. 58.

    Shahi, P. et al. The Transcriptional Repressor ZNF503/Zeppo2 Promotes Mammary Epithelial Cell Proliferation and Enhances Cell Invasion. J Biol Chem 290, 3803–3813 (2015).

  59. 59.

    Holland, D. G. et al. ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium. EMBO Mol Med 3, 167–180 (2011).

  60. 60.

    Ju, H., Jones, M. & Mishra, G. The prevalence and risk factors of dysmenorrhea. Epidemiol Rev 36, 104–113 (2014).

  61. 61.

    Pezet, S. & McMahon, S. B. Neurotrophins: mediators and modulators of pain. Annu Rev Neurosci 29, 507–538 (2006).

  62. 62.

    McKelvey, L., Shorten, G. D. & O’Keeffe, G. W. Nerve growth factor-mediated regulation of pain signalling and proposed new intervention strategies in clinical pain management. J Neurochem 124, 276–289 (2013).

  63. 63.

    Jayabalan, P. & Schnitzer, T. J. Tanezumab in the treatment of chronic musculoskeletal conditions. Expert Opin Biol Ther 1–10 (2016).

  64. 64.

    Lane, N. E. et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med 363, 1521–1531 (2010).

  65. 65.

    Brown, M. T. et al. Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial. Arthritis Rheum 65, 1795–1803 (2013).

  66. 66.

    Garlanda, C., Dinarello, C. A. & Mantovani, A. The interleukin-1 family: back to the future. Immunity 39, 1003–1018 (2013).

  67. 67.

    Hertelendy, F., Rastogi, P., Molnár, M. & Romero, R. Interleukin-1beta-induced prostaglandin E2 production in human myometrial cells: role of a pertussis toxin-sensitive component. Am J Reprod Immunol 45, 142–147 (2001).

  68. 68.

    Korita, D. et al. Cyclic mechanical stretching and interleukin-1alpha synergistically up-regulate prostacyclin secretion in cultured human uterine myometrial cells. Gynecol Endocrinol 18, 130–137 (2004).

  69. 69.

    Sooranna, S. R. et al. Myometrial prostaglandin E2 synthetic enzyme mRNA expression: spatial and temporal variations with pregnancy and labour. Mol Hum Reprod 12, 625–631 (2006).

  70. 70.

    Jabbour, H. N., Sales, K. J., Smith, O. P., Battersby, S. & Boddy, S. C. Prostaglandin receptors are mediators of vascular function in endometrial pathologies. Mol Cell Endocrinol 252, 191–200 (2006).

  71. 71.

    Pickles, V. R. Prostaglandins and dysmenorrhea. Historical survey. Acta Obstet Gynecol Scand Suppl 87, 7–12 (1979).

  72. 72.

    Hata, Y. et al. A nonsynonymous variant of IL1A is associated with endometriosis in Japanese population. J Hum Genet 58, 517–520 (2013).

  73. 73.

    Durack, D. T. In Oxford Textbook of Medicine (eds Warrell, D. A., Cox, T. M. & Firth, J. D.) 271–275 (Oxford University Press, USA, New York, NY, 2003).

  74. 74.

    Reimann, H. A. Habitual hyperthermia; premenstrual fever. J Am Med Assoc 132, 144 (1946).

  75. 75.

    Yamasaki, H., Oki, T., Iwamoto, I. & Douchi, T. Fourteen-year-old girl with recurrent luteal-phase-dependent episodes of high fever. J Obstet Gynaecol Res 37, 1166–1168 (2011).

  76. 76.

    Rutanen, E. M. et al. Recurrent fever associated with progesterone action and persistently elevated serum levels of immunoreactive tumor necrosis factor-alpha and interleukin-6. J Clin Endocrinol Metab 76, 1594–1598 (1993).

  77. 77.

    Nakamura, Y. & Hino, K. A case of ovulatory cycle-dependent symptoms in woman with previous interferon beta therapy. Endocr J 52, 377–381 (2005).

  78. 78.

    Jiang, Y. C., Wu, H. M., Cheng, K. H. & Sunny Sun, H. Menstrual cycle-dependent febrile episode mediated by sequence-specific repression of poly(ADP-ribose) polymerase-1 on the transcription of the human serotonin receptor 1A gene. Hum Mutat 33, 209–217 (2012).

  79. 79.

    Gris, P. et al. A novel alternatively spliced isoform of the mu-opioid receptor: functional antagonism. Mol Pain 6, 33 (2010).

  80. 80.

    Gordon, C. J., Rezvani, A. H. & Heath, J. E. Role of beta-endorphin in the control of body temperature in the rabbit. Neurosci Biobehav Rev 8, 73–82 (1984).

  81. 81.

    Tamura, Y., Shintani, M., Inoue, H., Monden, M. & Shiomi, H. Regulatory mechanism of body temperature in the central nervous system during the maintenance phase of hibernation in Syrian hamsters: involvement of β-endorphin. Brain Res 1448, 63–70 (2012).

  82. 82.

    Handelsman, L. et al. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse 13, 293–308 (1987).

  83. 83.

    Kapitzke, D., Vetter, I. & Cabot, P. J. Endogenous opioid analgesia in peripheral tissues and the clinical implications for pain control. Ther Clin Risk Manag 1, 279–297 (2005).

  84. 84.

    Abecasis, G. R. et al. An integrated map of genetic variation from 1,092 human genomes. Nature 491, 56–65 (2012).

  85. 85.

    Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81, 559–575 (2007).

  86. 86.

    Chang, C. C. et al. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience 4, 7 (2015).

  87. 87.

    Price, A. L. et al. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38, 904–909 (2006).

  88. 88.

    Yamaguchi-Kabata, Y. et al. Japanese population structure, based on SNP genotypes from 7003 individuals compared to other ethnic groups: effects on population-based association studies. Am J Hum Genet 83, 445–456 (2008).

  89. 89.

    Tian, C. et al. Analysis of East Asia genetic substructure using genome-wide SNP arrays. PLoS ONE 3, e3862 (2008).

  90. 90.

    Khor, S. S. et al. Genome-wide association study of self-reported food reactions in Japanese identifies shrimp and peach specific loci in the HLA-DR/DQ gene region. Sci Rep 8, 1069 (2018).

  91. 91.

    McCaffery, M. & Beebe, A. Pain: clinical manual for nursing practice (Mosby, St. Louis, 1989).

  92. 92.

    R_Core_Team. R: A Language and Environment for Statistical Computing.

  93. 93.

    Loh, P. R. et al. Reference-based phasing using the Haplotype Reference Consortium panel. Nat Genet 48, 1443–1448 (2016).

  94. 94.

    Loh, P. R., Palamara, P. F. & Price, A. L. Fast and accurate long-range phasing in a UK Biobank cohort. Nat Genet 48, 811–816 (2016).

  95. 95.

    Browning, S. R. & Browning, B. L. Rapid and accurate haplotype phasing and missing-data inference for whole-genome association studies by use of localized haplotype clustering. Am J Hum Genet 81, 1084–1097 (2007).

  96. 96.

    Browning, B. L. & Browning, S. R. Genotype Imputation with Millions of Reference Samples. Am J Hum Genet 98, 116–126 (2016).

  97. 97.

    Ward, L. D. & Kellis, M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res 40, D930–4 (2012).

  98. 98.

    Leslie, R., O’Donnell, C. J. & Johnson, A. D. GRASP: analysis of genotype-phenotype results from 1390 genome-wide association studies and corresponding open access database. Bioinformatics 30, i185–94 (2014).

  99. 99.

    Eicher, J. D. et al. GRASPv2.0: an update on the Genome-Wide Repository of Associations between SNPs and phenotypes. Nucleic Acids Res 43, D799–804 (2015).

  100. 100.

    Veyrieras, J. B. et al. Exon-specific QTLs skew the inferred distribution of expression QTLs detected using gene expression array data. PLoS One 7, e30629 (2012).

  101. 101.

    Veyrieras, J. B. et al. High-resolution mapping of expression-QTLs yields insight into human gene regulation. PLoS Genet 4, e1000214 (2008).

  102. 102.

    Welter, D. et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res 42, D1001–6 (2014).

  103. 103.

    Speir, M. L. et al. The UCSC Genome Browser database: 2016 update. Nucleic Acids Res 44, D717–25 (2016).

  104. 104.

    GTEx Analysis V7 download web-site.

  105. 105.

    Zhou, X. et al. The Human Epigenome Browser at Washington University. Nat Methods 8, 989–990 (2011).

  106. 106.

    Harrow, J. et al. GENCODE: The reference human genome annotation for The ENCODE Project. Genome Res 22, 1760–1774 (2012).

Download references


The authors would like to acknowledge the Genotype-Tissue Expression (GTEx) Project and Portal, which was essential to this study’s analyses. Support for the GTEx Project was provided by the Common Fund of the Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS. GTEx data used in this study were obtained on various dates in 2017–2018 and corresponds to GTEx Release V7.

Author information

Author notes

  1. Tetsuya Hirata, Kaori Koga and Todd A. Johnson contributed equally to this work.


  1. Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, 113-8655, Japan

    • Tetsuya Hirata
    • , Kaori Koga
    • , Tomoyuki Fujii
    •  & Yutaka Osuga
  2. StaGen Co., Ltd., Taito-ku, Tokyo, 111-0051, Japan

    • Todd A. Johnson
    • , Kazuyuki Nakazono
    • , Shigeo Kamitsuji
    •  & Naoyuki Kamatani
  3. EverGene Ltd., Shinjuku-ku, Tokyo, 163-1435, Japan

    • Ryoko Morino
    • , Masanori Akita
    • , Maiko Kawajiri
    • , Azusa Kami
    • , Asami Tada
    •  & Kenichi Ishikawa
  4. Life Science Group, Healthcare Division, Department of Healthcare Business, MTI Ltd., Shinjuku-ku, Tokyo, 163-1435, Japan

    • Yuria Hoshi
  5. LunaLuna Division, Department of Healthcare Business, MTI Ltd., Shinjuku-ku, Tokyo, 163-1435, Japan

    • Maaya Hine
    • , Miki Kobayashi
    •  & Nami Kurume


  1. Search for Tetsuya Hirata in:

  2. Search for Kaori Koga in:

  3. Search for Todd A. Johnson in:

  4. Search for Ryoko Morino in:

  5. Search for Kazuyuki Nakazono in:

  6. Search for Shigeo Kamitsuji in:

  7. Search for Masanori Akita in:

  8. Search for Maiko Kawajiri in:

  9. Search for Azusa Kami in:

  10. Search for Yuria Hoshi in:

  11. Search for Asami Tada in:

  12. Search for Kenichi Ishikawa in:

  13. Search for Maaya Hine in:

  14. Search for Miki Kobayashi in:

  15. Search for Nami Kurume in:

  16. Search for Tomoyuki Fujii in:

  17. Search for Naoyuki Kamatani in:

  18. Search for Yutaka Osuga in:


T.H., K.K., and T.A.J. wrote the manuscript. T.A.J. performed genetic and statistical analyses and made the figures and tables. K.N. wrote programs and performed analyses. S.K. supervised the statistical and bioinformatics analyses. R.M. and M. Ka. performed genotyping. R.M. also performed genotype QC. M. Ko. and N. Ku. prepared the questionnaires. A.T. performed management of DNA specimens and ID tracking. M.A. and M.H. performed study design. A.K., Y.H., and K.I. recruited subjects. N. Ka. supervised the statistical analysis and writing of the manuscript. T.F. and Y.O. supervised the analyses and writing of the manuscript.

Competing Interests

T.A.J., S.K., N.Ka., S.K. are employees of StaGen Co. Ltd. R.M., M.A., M.Ka., A.K., Y.H., A.T., K.I., M.H., M.Ko., and N.Ku are employees of EverGene/MTI. EverGene/MTI has applied for patents related to some of the female-related phenotype associations described in this report. N.Ka. is also Chairman of StaGen Co. Ltd. and a Director of the Tsukuba International Clinical Pharmacology Clinic. T.H., K.K., T.F. and Y.O. declare no competing interests.

Corresponding authors

Correspondence to Todd A. Johnson or Yutaka Osuga.

Electronic supplementary material

About this article

Publication history





Rights and permissions

Creative Commons BY

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.